Internal restructuring
Est; Alsace; Bas-Rhin
Location of affected unit(s)
Professional Services
Scientific, Architectural And Engineering Technical Activities
Scientific Research And Development
72.11 - Research and experimental development on biotechnology

80 - 120 jobs
Number of planned job losses
Job loss
Announcement Date
29 June 2015
Employment effect (start)
Foreseen end date


The French biotech company Transgene has announced it will close its clinical-scale biomanufacturing facility near Strasbourg with the loss of 120 jobs. The aim is to outsource production to third parties in the framework of a new strategy to move away from a vertical integration model to focus the resources on advancing Transgenes’ clinical development profile and R&D. The management took this decision after that the pharmaceutical group Novartis decided to stop its cooperation with Transgene in the immunotherapy field. The closure will lead to 120 job cuts of a total workforce employed at this site of 285 employees. However, the US subsidiary of Institut Mérieux, ABL, is expecting to take over the production in the site and may offer positions to 40 of the affected employees involved in manufacturing and related activities. 


  • 29 June 2015: Capital
  • 1 July 2015: Les Echos
  • 30 June 2015: L'usine Nouvelle
  • 1 July 2015: BioPharma-reporter.com


Eurofound (2015), Transgene, Internal restructuring in France, factsheet number 83874, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/83874.